Estrella Immunopharma adds fifth site for Phase I/II EB103 trial in B-cell non-Hodgkin’s lymphoma
ESLA•Estrella Immunopharma activated Intermountain Health LDS Hospital as the fifth site for its Phase I/II STARLIGHT-1 trial of EB103, which is evaluating patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma.
1. Trial site expansion
Intermountain Health LDS Hospital in Salt Lake City is expected to begin screening and enrolling patients following site initiation. The ongoing expansion phase evaluates safety and efficacy, with results expected to inform a future pivotal trial strategy.
